Overview of Dr. Korde
Dr. Neha Korde is an oncologist in Montvale, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Bergen, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 12 years. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 15 doctors at Memorial Sloan Kettering Bergen who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
225 Summit Avenue
Montvale, NJ 07645
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Temple University HospitalResidency, Internal Medicine, 2005 - 2008
Rutgers Robert Wood Johnson Medical SchoolClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2016 - 2025
NY State Medical License 2008 - 2025
NC State Medical License 2020 - 2022
PA State Medical License 2005 - 2008- American Board of Internal Medicine Hematology
Clinical Trials
- High Dose Carfilzomib for Newly Diagnosed Myeloma Start of enrollment: 2016 Oct 01
- Mobile Health Device Study for Myeloma Patients Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- 128 citationsCheckpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with MyelomaMattias Carlsten, Neha Korde, Ritesh Kotecha, Robert Reger, Simona Bor
Clinical Cancer Research. 2016-11-01 - 100 citationsA phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myelomaNeha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan
Haematologica. 2014-06-01 - 104 citationsGPRC5D-Targeted CAR T Cells for Myeloma.Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte
The New England Journal of Medicine. 2022-09-29
Abstracts/Posters
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban ProphylaxisNeha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...Neha Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Multiple Myeloma Research Foundation (MMRF) and Memorial Sloan Kettering (MSK) Cancer Center Collaborate on Minimal Residual Disease (MRD) Study in Multiple MyelomaSeptember 13th, 2016
Sloan Kettering Taps Mobile Tools for Insight on Cancer TreatmentJuly 25th, 2016
Medidata Collaborates with Leading New York Cancer Center to Expand the Use of mHealth Technology in Oncology CareJuly 20th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
